Elicia Penuel

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012 · 1.1K citations · Full text

Medicine, Kinase Inhibitors, Anti-cancer Agent +6

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 741 citations · Full text

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 390 citations

Lymphoid Neoplasia, Bispecific Antibody, Medicine +7

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani et al. · The Lancet Haematology · 2019 · 243 citations · Full text

Lymphoid Neoplasia, Pinatuzumab Vedotin, Medicine +9

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang et al. · Cancer Research · 2011 · 223 citations · Full text

Breast Oncology, Her2 Homodimers, Immunology +17